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AbstrAct:
The  PI3K  pathway  is  frequently  activated  in  tumors,  most  commonly  through 
p110α  mutation  or  PTEN  deletion.  In  contrast  to  p110α,  p110β  is  oncogenic 
when  over-expressed  in  the  wild-type  state,  suggesting  that  its  regulation  by 
p85  is  different  than  that  of  p110α.  In  this  perspective,  we  summarize  recent 
data  concerning  the  regulation  of  p110β,  which  shows  that  wild-type  p110β 
acts like an oncogenic mutant of p110α. We also discuss the significance of this 
altered  regulation  in  tumor  models  of  PTEN  deletion,  as  well  as  the  potential 
implications  of  the  unique  p110β  regulation  on  GPCR-driven  tumorigenesis.
Phosphoinositide 3-kinases (PI3Ks) are a family 
of enzymes that catalyze the phosphorylation of the D3 
hydroxyl of the inositol ring in phosphoinositides. The three 
classes of PI3Ks are distinguished by sequence homology 
and substrate specificity in vivo [1]. Class I PI3Ks signal 
downstream from Receptor Tyrosine Kinases (RTKs) and 
G-protein coupled receptors (GPCRs) and phosphorylate 
PI(4,5)P2 to generate PI(3,4,5)P3 (PIP3), an important 
second messenger that recruits proteins containing a PH 
domain [2]. Class IA PI3Ks are obligate heterodimers of 
a catalytic subunit (p110α, β, δ) with regulatory subunit 
(p85α, p85β, p55α, p50α, and p55γ), and Class IB PI3Ks 
are dimers of a p110γ catalytic subunit and p101 or p87 
regulatory subunits. The canonical classification of PI3Ks 
defines Class IA PI3Ks as signaling downstream from 
RTKs [3], whereas Class IB PI3Ks signal downstream 
from GPCRs [1]. This distinction has been questioned by 
data showing that the p110β isoform of class IA PI3Ks 
is  activated  by  Gβγ  subunits  downstream  of  GPCRs, 
similar to p110γ [4-7]. A large number of recent studies 
has defined signaling differences between the p110β and 
the p110α catalytic subunits (reviewed in [8]).
Class  I  PI3K  signaling  is  frequently  amplified 
in tumors, most commonly by activating mutations in 
PIK3CA (which codes for p110α) and disabling mutation 
or deletion of PTEN (phosphatase and tensin homolog) 
[9]. In contrast to p110α, no oncogenic mutations have 
been found in any of the other class I PI3K catalytic 
subunits.  However,  p110α  is  only  oncogenic  when 
mutated, whereas p110-β, -γ, and -δ are oncogenic when 
expressed in their wild-type form [10]. This suggests that 
the regulation of p110β and p110δ is different than that 
of p110α. Recent studies have shown that p110β but not 
p110α has essential roles in tumorigenesis in PTEN-null 
mouse  models  and  cell  lines  [11,  12].  p110β  has  also 
been implicated in the growth of ErbB2-driven mammary 
tumors [13] and in Ras-driven tumors [12]. Thus, defining 
the mechanism of p110β regulation could have important 
clinical implications.
We have previously shown that C2-iSH2 contacts 
formed by N345 of p110α with D560/N564 in p85 are 
required  for  full  inhibition  of  p110α  activity  by  p85. 
These contacts are disrupted by an N345K mutation 
in  p110  and  by  point  mutants  (p85D560K/N564K)  or 
truncations (p85-572STOP) in p85 [14, 15]. Furthermore, 
we described an assay to measure the presence or loss 
of the C2-iSH2 interface. Wild-type p110α is strongly 
inhibited by p85 but minimally inhibited by p85D560K/
N564K or p85-572STOP. In contrast, p110α-N345K shows 
the same minimal inhibition by wild type p85 or the 
p85D560K/N564K and p85-572STOP mutants. Therefore, 
the differential regulation of p110 molecules by wild-type 
versus mutant p85 can be used to detect the presence of an 
intact C2-iSH2 interface.
We have now used this assay to study the regulation 
of p110β as compared to the other class IA PI3K catalytic 
subunits,  p110α  and  p110δ  [16].  Sequence  alignment 
of p110β with p110α shows a crucial difference in the 
C2 domain of p110β, with K342 of p110β aligned with 
N345 of p110α. This makes wild-type p110β analogous 
to  the  oncogenic  p110α  mutant  N345K.  Using  our Oncotarget 2010; 1:  729 - 733 730 www.impactjournals.com/oncotarget
assay for the C2-iSH2 interface, we showed that p110β 
is minimally inhibited by wild-type p85 or p85 572STOP, 
similar  to  the  p110α  N345K  mutant. A  mutant  p110β-
K342N that mimics the C2-iSH2 interface in p110α is less 
transforming  than  wild-type  p110β,  and  shows  a  gain-
of-function for differential regulation by wild-type p85 
versus  p85-572STOP.  p110β-K342N  is  still  regulated  by 
Gβγ subunits, similar to wild-type p110β. 
Further analysis of the role of the C2-iSH2 interface 
in  the  transforming  potential  of  p110β  was  performed 
using  p110α/β  chimeras.  Chimeric  p110α/β  molecules 
having the C2 of p110α showed decreased transforming 
potential  as  compared  to  p110β,  whereas  a  p110α/β 
chimera containing the C2 domain of p110β shows the 
high transforming potential characteristic of p110β. Our 
data show that the transforming potential of p110β is due, 
at least in part, to the disruption of the inhibitory interface 
between the C2 of p110β and the iSH2 domain of p85, 
which leads to high basal p110β signaling [16]. In contrast 
to p110β, p110δ showed the differential regulation by wild 
type versus mutant p85 that is characteristic of an intact 
C2-iSH2 interface. Given that p110δ is also transforming 
in its wild type state, its enhanced transforming potential 
must be due to other factors [16].
In addition to the impact of a disrupted C2-iSH2 
interface on the transforming potential of p110β, the loss 
of  p85  inhibition  might  explain  the  inability  of  p110β 
to  signal  downstream  of  receptor  tyrosine  kinases  [7]. 
Activation of class IA PI3Ks by phosphopeptides involves 
the disruption of an inhibitory contact between the nSH2 
domain of p85 and the helical domain of p110 [17]. If 
p110β is less inhibited by p85 under basal conditions, this 
would lead to a loss of activation of p85/p110β dimers by 
activated RTKs. This is supported by recent data showing 
that cancer specific p85 mutations in the nSH2 and iSH2 
domains function solely through p110α, not p110β [18]. 
Several studies have suggested that p110β is the sole 
class IA PI3K catalytic subunit required for initiation and 
Figure 1: Model for p110β dependency in PTEN null tumors. p85 binds to both p110β and PTEN, allowing negative regulation 
of basal p110β activity by PTEN. This ensures that normal (PTEN+/+) cells maintain a low basal level of PIP3 at the plasma membrane, 
leading to low basal signaling and controlled cell growth. In contrast, in PTEN-/- cells, basal p110β activity is not countered by p85/p110β-
associated PTEN, leading to high basal PIP3 levels in the membrane, enhanced activation of Akt and S6K1, and uncontrolled cell growth and 
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maintenance of PTEN-null driven tumors [11, 12, 19]. It is 
also interesting that PTEN seems to specifically associate 
with p85/p110β, an interaction mediated by the SH3 and 
BH domains of p85 and leading to enhanced PTEN catalytic 
activity [20, 21]. The association of p110β with PTEN is 
consistent with our data showing that purified p110β is 
relatively active under basal conditions [16], as it provides 
a regulatory mechanism to prevent uncontrolled signaling 
in normal cells. Thus, under normal growth conditions, the 
activity of p110β is antagonized by the PTEN associated 
with  the  p85/p110β  dimer,  thereby  controlling  steady-
state PIP3 levels. However, in conditions where PTEN 
expression or activity is lost, the activity of p110β is no 
longer countered by the phosphatase activity of PTEN, 
leading to high levels of PIP3 and downstream signaling. 
This may provide a model for the deregulation of PI3K 
signaling  and  p110β-dependence  of  PTEN-null  tumors 
(Figure 1). It is also interesting to note that PTEN has 
been shown to function downstream of anti-migratory 
GPCRs [22] and to negatively regulate CXCR4-mediated 
chemotaxis [23]. This suggests that PTEN might also 
be  acting  as  a  negative  regulator  of  p110β  activation 
downstream of GPCRs involved in the regulation of cell 
motility. 
p110β  is  essential  for  survival  and  has  unique 
functions that are not redundant with other class IA PI3K 
catalytic subunits, as knockout mice show embryonic 
lethality [24]. p110β is the sole class IA PI3K subunit 
that signals downstream of GPCRs via direct Gβγ binding 
and activation, and the only GPCR-regulated PI3K 
in  non-hematopoietic  cells.  The  mechanism  of  Gβγ-
mediated regulation of p110β is not well characterized. 
Previous studies with p110γ have shown that Gβγ binds 
to  N-terminal  and  C-terminal  regions  of  p110γ  and 
activates the kinase activity of p110γ [25]. Gβγ also binds 
to p101 to mediate membrane recruitment of the p101/
p110γ complex [26]. For p110β, activation requires direct 
interaction  of  Gβγ  subunits  with  the  p110β  catalytic 
subunit and appears to be independent of the p85 regulatory 
subunit [27]. Using chimeric p110α/β molecules, we have 
narrowed the interaction interface with Gβγ to the helical-
kinase  domains  of  p110β  [16].  Further  delineation  of 
this interacting interface will be important for targeting 
the  subset  of  p110β  functions  that  are  downstream  of 
GPCRs. Mutations in the Gβγ binding site of p110β will 
be important for defining the role of p110β in initiating 
GPCR-driven tumors, and for studying its contribution to 
invasion and metastasis triggered by GPCR ligands. 
In addition to transmitting signals downstream of 
GPCRs, p110β has been shown to be essential for clathrin-
mediated endocytosis [12, 13] and autophagy [28]. These 
roles are suggested to be mediated by interactions with 
Rab5, and are unique in that they are kinase-independent 
functions of p110β. Furthermore, p110β regulates integrin 
mediated signaling in platelets [29, 30], and may have 
important antithrombotic roles  [31]. This is intriguing 
because integrin signaling and integrin and focal adhesion 
endocytosis, which is mediated by clathrin [32], are 
essential for cell migration [33]. It will be important 
to determine whether the role of p110β in endocytosis 
is related to its functions in cancer cell migration and 
invasion. 
p110β is unique among the class IA PI3Ks, both in 
terms of functions and regulation. The isoform-specific 
regulation  of  p110β  by  Gβγ  and  Rab5,  as  well  as  its 
critical roles in a subset of tumor types, may lead to novel 
therapeutic approaches for the treatment of human cancer.
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